Vnitr Lek 2024, 70(6):E10-E12 | DOI: 10.36290/vnl.2024.080

Primary and secondary prevention of stroke and arterial hypertension

Jiří Widimský
III. interní klinika VFN a 1. LF UK Praha

Strokes are among the most common cardiovascular complications, with arterial hypertension being considered the most significant risk factor. It is estimated that more than 50% of strokes are caused by hypertension, and high blood pressure alone increases the risk of stroke by 3-4 times! Furthermore, hypertension is an independent risk factor for the development of atrial fibrillation. The following brief summary addresses approaches to antihypertensive treatment in the primary and secondary prevention of strokes. Adequate control of hypertension through pharmacological treatment leads (among other benefits) to a significant reduction in the risk of both ischemic and hemorrhagic strokes. Early initiation of antihypertensive treatment also slows the progression of cognitive disorders. This text briefly summarizes current approaches to pharmacological antihypertensive intervention. The treatment of hypertension in the acute phase of a stroke depends on the underlying cause, the treatment used, and the time elapsed since the onset of symptoms. Details are beyond the scope of this text.

Keywords: primary and secondary prevention, stroke, hypertension, therapy.

Accepted: September 19, 2024; Published: October 3, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Widimský J. Primary and secondary prevention of stroke and arterial hypertension. Vnitr Lek. 2024;70(6):E10-12. doi: 10.36290/vnl.2024.080.
Download citation

References

  1. Widimský J, et al. Hypertenze, 5.vydání, 2019, 1-553, Maxdorf.
  2. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs--overview and meta-analyses. J Hypertens. 2015;33:195-211. Go to original source... Go to PubMed...
  3. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses. J Hypertens 2015;33:1321-41. Go to original source... Go to PubMed...
  4. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-28. Go to original source... Go to PubMed...
  5. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352:1347-51. Go to original source... Go to PubMed...
  6. Tzourio C, Anderson C, Chapman N et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003;163:10. Go to original source... Go to PubMed...
  7. Widimský J, Filipovský J, Ceral J, et al. Diagnostické a léčebné postupy u arteriální hypertenze - verze 2022. Doporučení České společnosti pro hypertenzi. Hypertenze a KV prevence, suplementum 2022, str. 1-25.
  8. Group SR, Wright JT, Jr., Williamson JD, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373:2103-2116. Go to original source... Go to PubMed...
  9. Group AS, Cushman WC, Evans GW, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-85. Go to original source... Go to PubMed...
  10. Bulpitt CJ, Becket NS, Cooke J, et al. Hypertension in the Very Elderly Trial (HYVET) Working Group. Results from the pilot study for Hypertension in the Very Elderly Trial.J Hypertens. 2003;21:2409-17. Go to original source... Go to PubMed...
  11. Mancia G, Kreutz R, et al. 2023 ESH Guidelines for the management of Arterial hypertension. Journal of hypertension. 2023;41(12):1874-2071. Go to original source... Go to PubMed...
  12. Group PC. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-41. Go to original source... Go to PubMed...
  13. Group SPSS, Benavente OR, Coffey CS, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;382:507-15. Go to original source... Go to PubMed...
  14. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387:957-967. Go to original source... Go to PubMed...
  15. Dawson J, Bejot Y, Christensen LM, et al. European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack. Eur Stroke J. 2022; 7:I-II. Go to original source... Go to PubMed...
  16. Sandset E, Anderson CS, Bath5 PH, et al. European Stroke Organisation (ESO) guidelines on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage. European Stroke Journal 2021, Vol. 6(2)X48-L89. Go to original source... Go to PubMed...
  17. Widimský J. Léčba hypertenze v akutní fázi cévních mozkových příhod. Hypertenze a KV prevence, 2024, 2 v tisku.




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.